Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10174463 | 0.94 | L3MBTL1 (0.48) | L3MBTL1MAPK1ALDH1A1ADORA3KDM4E | |
| SCHEMBL7208457 | 0.89 | TLR7 (0.42) | L3MBTL1MAPK1ALDH1A1KDM4EGAA | |
| SCHEMBL7205405 | 0.88 | MAPK1 (0.48) | MAPK1ADORA3TSHR | |
| SCHEMBL2060499 | 0.87 | KDM4E (0.47) | L3MBTL1MAPK1ALDH1A1KDM4EGAA | |
| SCHEMBL7205545 | 0.87 | TLR7 (0.47) | — | |
| SCHEMBL7208584 | 0.87 | MAPK1 (0.47) | MAPK1ADORA3TSHR | |
| SCHEMBL7206750 | 0.87 | CXCL12 (0.45) | L3MBTL1MAPK1ALDH1A1KDM4EGAA | |
| SCHEMBL7210239 | 0.87 | ABCB1 (0.50) | MAPK1ALDH1A1ADORA3GAATSHR | |
| SCHEMBL7204088 | 0.86 | TLR7 (0.47) | ADORA3 | |
| SCHEMBL3874062 | 0.85 | MAPK1 (0.56) | L3MBTL1MAPK1ALDH1A1ADORA3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822407-B2 | Preparation of conjugates comprising adenine derivatives and allergenic proteins and their use for specific immunotherapy of allengenic diseases | UNIVERSITA' DEGLI STUDI DI FIRENZE (IT) | 2014-09-02 | — | — | US | disclosed |
| US-8822407-B2 | Preparation of conjugates comprising adenine derivatives and allergenic proteins and their use for specific immunotherapy of allengenic diseases | UNIVERSITA' DEGLI STUDI DI FIRENZE (IT) | 2014-09-02 | — | — | US | disclosed |
| US-8822407-B2 | Preparation of conjugates comprising adenine derivatives and allergenic proteins and their use for specific immunotherapy of allengenic diseases | UNIVERSITA' DEGLI STUDI DI FIRENZE (IT) | 2014-09-02 | — | — | US | disclosed |
| EP-2600899-B1 | PREPARATION OF CONJUGATES COMPRISING ADENINE DERIVATIVES AND ALLERGENIC PROTEINS AND THEIR USE FOR SPECIFIC IMMUNOTHERAPY OF ALLERGENIC DISEASES | UNIV FIRENZE (IT) | 2014-06-25 | — | — | EP | disclosed |
| US-20130136764-A1 | PREPARATION OF CONJUGATES COMPRISING ADENINE DERIVATIVES AND ALLERGENIC PROTEINS AND THEIR USE FOR SPECIFIC IMMUNOTHERAPY OF ALLENGENIC DISEASES | UNIVERSITA ' DEGLI STUDI DI FIRENZE (IT) | 2013-05-30 | — | — | US | disclosed |
| US-20130136764-A1 | PREPARATION OF CONJUGATES COMPRISING ADENINE DERIVATIVES AND ALLERGENIC PROTEINS AND THEIR USE FOR SPECIFIC IMMUNOTHERAPY OF ALLENGENIC DISEASES | UNIVERSITA ' DEGLI STUDI DI FIRENZE (IT) | 2013-05-30 | — | — | US | disclosed |
| US-20130136764-A1 | PREPARATION OF CONJUGATES COMPRISING ADENINE DERIVATIVES AND ALLERGENIC PROTEINS AND THEIR USE FOR SPECIFIC IMMUNOTHERAPY OF ALLENGENIC DISEASES | UNIVERSITA ' DEGLI STUDI DI FIRENZE (IT) | 2013-05-30 | — | — | US | disclosed |
| EP-1035123-B1 | NOVEL HETEROCYCLIC COMPOUNDS | SUMITOMO PHARMA (JP) | 2003-08-20 | — | — | EP | disclosed |
| US-6329381-B1 | INTERFERONS, VIRICIDES AND ANTICARCINOGENIC AGENTS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130136764-A1 | PREPARATION OF CONJUGATES COMPRISING ADENINE DERIVATIVES AND ALLERGENIC PROTEINS AND THEIR USE FOR SPECIFIC IMMUNOTHERAPY OF ALLENGENIC DISEASES | ENPP2, LTC4S, C3AR1 | L3MBTL1 2030/4885MAPK1 2541/4885PLA2G2A 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.